sur Vita 34 AG (isin : DE000A0BL849)
Subsidiaries of Vita 34 Reach Agreement with US Licensor
Leipzig, 9 August 2024 – Vita 34 AG has announced that its subsidiaries, FamiCordTx S.A. and Polski Bank Komórek Macierzystych sp. z o.o. (PBKM), have reached an agreement with a U.S. biotechnology company, resolving a prior lawsuit.
The dispute began on 27 September 2023 when FamiCordTx and PBKM filed a legal action due to the Licensor's failure to comply with a CAR-T technology license agreement essential for cancer immunotherapy development. The litigation alleged material breach of the agreement by the Licensor.
After continuous negotiations, the parties finalized a termination agreement of the original license and established a new know-how licensing agreement. This new deal ensures FamiCordTx and PBKM retain access to necessary CAR-T technology, with reduced royalty payments for commercial use or sale without milestone payments.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Vita 34 AG